Q1 Earnings Forecast for SPRY Issued By Northland Securities

Key Points

• Northland Securities' analyst C. Byrnes forecasts Q1 2026 EPS of ($0.47), maintains an "Outperform" rating with a $25.00 price objective, and projects FY2026 EPS of ($1.50) and FY2028 EPS of $0.30.
• ARS reported ($0.42) EPS on March 9, matching consensus, and revenue of $28.09M which beat estimates, despite a deeply negative net margin and return on equity.
• SPRY trades near $8.05 with a market cap around $799M, a negative P/E of -4.6, a 12‑month range of $6.66–$18.90, and roughly 68% institutional ownership.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Northland Securities issued their Q1 2026 EPS estimates for ARS Pharmaceuticals in a research note issued to investors on Thursday, April 9th. Northland Securities analyst C. Byrnes expects that the company will post earnings of ($0.47) per share for the quarter. Northland Securities has a "Outperform" rating and a $25.00 price objective on the stock. The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Northland Securities also issued estimates for ARS Pharmaceuticals' Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.50) EPS, FY2027 earnings at ($0.75) EPS and FY2028 earnings at $0.30 EPS.

Several other research firms also recently commented on SPRY. Weiss Ratings reissued a "sell (d-)" rating on shares of ARS Pharmaceuticals in a research report on Wednesday, January 21st. Leerink Partners set a $26.00 price objective on shares of ARS Pharmaceuticals and gave the stock an "outperform" rating in a report on Tuesday, March 10th. Finally, Zacks Research raised shares of ARS Pharmaceuticals from a "strong sell" rating to a "hold" rating in a report on Wednesday, February 25th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $28.25.

ARS Pharmaceuticals Stock Performance

SPRY stock opened at $8.05 on Monday. The company has a quick ratio of 7.06, a current ratio of 7.28 and a debt-to-equity ratio of 1.47. The company has a market capitalization of $799.34 million, a price-to-earnings ratio of -4.60 and a beta of 0.86. ARS Pharmaceuticals has a 12 month low of $6.66 and a 12 month high of $18.90. The firm has a 50 day moving average of $8.83 and a two-hundred day moving average of $9.60.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last posted its earnings results on Monday, March 9th. The company reported ($0.42) EPS for the quarter, hitting the consensus estimate of ($0.42). The company had revenue of $28.09 million during the quarter, compared to the consensus estimate of $25.58 million. ARS Pharmaceuticals had a negative net margin of 203.25% and a negative return on equity of 100.29%.

Institutional Trading of ARS Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SPRY. Royal Bank of Canada boosted its holdings in ARS Pharmaceuticals by 1,075.3% in the 1st quarter. Royal Bank of Canada now owns 18,547 shares of the company's stock valued at $234,000 after purchasing an additional 16,969 shares during the period. AQR Capital Management LLC bought a new stake in ARS Pharmaceuticals in the 1st quarter valued at $140,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in ARS Pharmaceuticals by 13.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 279,840 shares of the company's stock valued at $3,520,000 after purchasing an additional 32,526 shares during the period. JPMorgan Chase & Co. boosted its holdings in ARS Pharmaceuticals by 7.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 34,560 shares of the company's stock valued at $603,000 after purchasing an additional 2,357 shares during the period. Finally, Legal & General Group Plc boosted its holdings in ARS Pharmaceuticals by 55.1% in the 2nd quarter. Legal & General Group Plc now owns 54,825 shares of the company's stock valued at $957,000 after purchasing an additional 19,484 shares during the period. 68.16% of the stock is owned by institutional investors.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.